期刊
VACCINE
卷 25, 期 13, 页码 2451-2457出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2006.09.019
关键词
pneumococcal conjugate vaccine; prevention; immunogenicity; HIV
资金
- PHS HHS [1U19A153217] Funding Source: Medline
The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4-92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI -7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of >0.2 mu g/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age. (C) 2006 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据